RT Journal Article
SR Electronic
T1 Impact of HIV Infection on COVID-19 Outcomes Among Hospitalized Adults in the U.S.
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.04.05.21254938
DO 10.1101/2021.04.05.21254938
A1 Durstenfeld, Matthew S.
A1 Sun, Kaiwen
A1 Ma, Yifei
A1 Rodriguez, Fatima
A1 Secemsky, Eric A.
A1 Parikh, Rushi V.
A1 Hsue, Priscilla Y.
YR 2021
UL http://medrxiv.org/content/early/2021/04/07/2021.04.05.21254938.1.abstract
AB Background Whether HIV infection is associated with differences in clinical outcomes among people hospitalized with COVID-19 is uncertain.Objective To evaluate the impact of HIV infection on COVID-19 outcomes among hospitalized patients.Methods Using the American Heart Association’s COVID-19 Cardiovascular Disease registry, we used hierarchical mixed effects models to assess the association of HIV with in-hospital mortality accounting for patient demographics and comorbidities and clustering by hospital. Secondary outcomes included major adverse cardiac events (MACE), severity of illness, and length of stay (LOS).Results The registry included 21,528 hospitalization records of people with confirmed COVID-19 from 107 hospitals in 2020, including 220 people living with HIV (PLWH). PLWH were younger (56.0+/-13.0 versus 61.3+/-17.9 years old) and more likely to be male (72.3% vs 52.7%), Non-Hispanic Black (51.4% vs 25.4%), on Medicaid (44.5% vs 24.5), and active tobacco users (12.7% versus 6.5%).Of the study population, 36 PLWH (16.4%) had in-hospital mortality compared with 3,290 (15.4%) without HIV (Risk ratio 1.06, 95%CI 0.79-1.43; risk difference 0.9%, 95%CI −4.2 to 6.1%; p=0.71). After adjustment for age, sex, race, and insurance, HIV was not associated with in-hospital mortality (aOR 1.13; 95%CI 0.77-1.6; p 0.54) even after adding body mass index and comorbidities (aOR 1.15; 95%CI 0.78-1.70; p=0.48). HIV was not associated with MACE (aOR 0.99, 95%CI 0.69-1.44, p=0.91), severity of illness (aOR 0.96, 95%CI 0.62-1.50, p=0.86), or LOS (aOR 1.03; 95% CI 0.76-1.66, p=0.21).Conclusion HIV was not associated with adverse outcomes of COVID-19 including in-hospital mortality, MACE, or severity of illness.Condensed Abstract We studied 21,528 patients hospitalized with COVID-19 at 107 hospitals in AHA’s COVID-19 registry to examine the association between HIV and COVID-19 outcomes. More patients with HIV were younger, male, non-Hispanic Black, on Medicaid and current smokers. HIV was not associated with worse COVID-19 in-hospital mortality (Risk ratio 1.06, 95%CI 0.79-1.43; p=0.71) even after adjustment (aOR 1.15; 95%CI 0.78-1.70; p=0.48). HIV was also not associated with MACE (aOR 0.99, 95%CI 0.69-1.44, p=0.91) or severity of illness (aOR 0.96, 95%CI 0.62-1.50, p=0.86. Our findings do not support that HIV is a major risk factor for adverse COVID-19 outcomes.Competing Interest StatementDisclosures: MSD, KS, and YM have no disclosures. FR has received consulting fees from Novartis, Janssen, NovoNordisk, and HealthPals unrelated to this work. EAS reports unrelated research grants to BIDMC: AstraZeneca, BD, Boston Scientific, Cook, CSI, Laminate Medical, Medtronic and Philips and unrelated consulting/speaking fees from Abbott, Bayer, BD, Boston Scientific, Cook, CSI, Inari, Janssen, Medtronic, Philips, and VentureMed. RVP reports unrelated research support Janssen and Infraredx; consulting fees from Abbott Vascular; and scientific advisory board (minor equity interest) of Stallion Cardio, DocVocate, and HeartCloud. PYH has received honoraria from Gilead and Merck, research grant from Novartis, unrelated to this work..Funding StatementSources of funding: The authors did not receive payment for any aspects of the submitted work. AHA's suite of Registries is funded by multiple industry sponsors. AHA's COVID-19 CVD Registry is partially supported by The Gordon and Betty Moore Foundation (Palo Alto, California). Dr. Durstenfeld is supported by NIH/NHLBI 5T32HL007731-28. Dr. Rodriguez is funded by NIH/NHLBI K01 HL 144607 and the American Heart Association/Robert Wood Johnson Harold Amos Medical Faculty Development Program. Dr. Secemsky is supported by NIH/NHLBI K23HL150290. Dr. Parikh is supported by AHA grant 18CDA34110335. Dr. Hsue is supported by NIH/NIAID 2K24AI112393-06.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:University of California, San Francisco provided IRB approval for this study. A waiver of consent was granted and the analysis was conducted with a deidentified dataset.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesDe-identified data from the American Heart Association's COVID-19 registry is available through the AHA's Precision Medicine Platform. Requests to access the data should be made through the AHA COVID registry after submitting a proposal: https://www.heart.org/en/professional/quality-improvement/covid-19-cvd-registry/covid-19-cvdregistry-research-opportunities.(HIV)human immunodeficiency virus(PLWH)people living with HIV(MACE)major adverse cardiac events(aOR)adjusted odds ratio(LOS)length of stay(AHA)American Heart Association(AIDS)acquired immunodeficiency syndrome(BMI)body mass index(COVID-19)coronavirus disease 2019